virosomes

Summary

Summary: Semi-synthetic complex derived from nucleic-acid free viral particles. They are essentially reconstituted viral coats, where the infectious nucleocapsid is replaced by a compound of choice. Virosomes retain their fusogenic activity and thus deliver the incorporated compound (antigens, drugs, genes) inside the target cell. They can be used for vaccines (VACCINES, VIROSOME), drug delivery, or gene transfer.

Top Publications

  1. ncbi Virosomal adjuvanted antigen delivery systems
    Christian Moser
    Virology, Berna Biotech Ltd, Bern, Switzerland
    Expert Rev Vaccines 2:189-96. 2003
  2. ncbi Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells
    Mario Amacker
    Pevion Biotech Ltd, Rehhagstrasse 79, CH 3018 Bern, Switzerland
    Int Immunol 17:695-704. 2005
  3. ncbi Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges
    Morgane Bomsel
    Mucosal Entry of HIV 1 and Mucosal Immunity, Cell Biology and Host Pathogen Interactions Department, Cochin Institute, CNRS UMR 8104, 22 rue Mechain, Paris, France
    Immunity 34:269-80. 2011
  4. pmc Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP
    Gabriel Kristian Pedersen
    The Gade Institute, University of Bergen, Norway
    PLoS ONE 6:e26973. 2011
  5. ncbi Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine
    Christian Herzog
    Berna Biotech AG, Rehhagstrasse 79, 3018 Berne, Switzerland
    Vaccine 27:4381-7. 2009
  6. pmc Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes
    Geert Leroux-Roels
    Center for Vaccinology CEVAC, Ghent University Hospital, Ghent, Belgium
    PLoS ONE 8:e55438. 2013
  7. ncbi Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs
    Diana Felnerova
    Berna Biotech Ltd, Rehhagstrasse 79, CH 3018, Berne, Switzerland
    Curr Opin Biotechnol 15:518-29. 2004
  8. ncbi Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation
    Toon Stegmann
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen and University of Groningen, 9700 RB, Groningen, The Netherlands
    Vaccine 28:5543-50. 2010
  9. ncbi Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs
    J De Jonge
    University Medical Center Groningen, Department of Medical Microbiology, Groningen, The Netherlands
    Gene Ther 13:400-11. 2006
  10. ncbi Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool
    Yasufumi Kaneda
    Osaka University, Graduate School of Medicine, Division of Gene Therapy Science, Suita, Osaka, Japan
    Expert Opin Drug Deliv 7:1079-93. 2010

Research Grants

  1. Adjuvants and Virosomal Vaccines for the Elderly
    Janet E McElhaney; Fiscal Year: 2011
  2. KINETICS AND MECHANISMS OF VIRUS-CELL MEMBRANE FUSION
    Nejat Duzgunes; Fiscal Year: 1992
  3. DEVELOPMENT OF CFTR AS A THERAPEUTIC PROTEIN
    Alan Smith; Fiscal Year: 1991
  4. MEMBRANE FUSION
    JOSEPH BENTZ; Fiscal Year: 1992
  5. PARAMYXOVIRUS MEMBRANE FUSION
    TRUDY MORRISON; Fiscal Year: 2005
  6. Cloning Kawasaki Disease-specific antigens
    Anne Rowley; Fiscal Year: 2005
  7. Inhibiting poxvirus phosphatases: therapy and biodefense
    Paula Traktman; Fiscal Year: 2004
  8. VACCINIA ENCODED KINASES AND PHOSPHATASES
    Paula Traktman; Fiscal Year: 2003
  9. JEOL 2100 LaB6 Transmission Electron Microscope with GATAN Ultrascan 1000 Camera
    Paula Traktman; Fiscal Year: 2006
  10. VACCINIA ENCODED KINASES AND PHOSPHATASES
    Paula Traktman; Fiscal Year: 2009

Detail Information

Publications173 found, 100 shown here

  1. ncbi Virosomal adjuvanted antigen delivery systems
    Christian Moser
    Virology, Berna Biotech Ltd, Bern, Switzerland
    Expert Rev Vaccines 2:189-96. 2003
    ..The principles of the concept, immunoadjuvant action and application of virosomes in two currently licensed vaccines are detailed, with specific reference to the induction of both humoral and ..
  2. ncbi Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells
    Mario Amacker
    Pevion Biotech Ltd, Rehhagstrasse 79, CH 3018 Bern, Switzerland
    Int Immunol 17:695-704. 2005
    ..We improved an existing vaccine platform based on immunopotentiating reconstituted influenza virosomes (IRIVs) for efficient delivery of peptide epitopes to the MHC class I antigen presentation pathway...
  3. ncbi Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges
    Morgane Bomsel
    Mucosal Entry of HIV 1 and Mucosal Immunity, Cell Biology and Host Pathogen Interactions Department, Cochin Institute, CNRS UMR 8104, 22 rue Mechain, Paris, France
    Immunity 34:269-80. 2011
    ..via both the intramuscular and intranasal routes with an HIV-1 vaccine made of gp41-subunit antigens grafted on virosomes, a safe delivery carrier approved in humans with self-adjuvant properties...
  4. pmc Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP
    Gabriel Kristian Pedersen
    The Gade Institute, University of Bergen, Norway
    PLoS ONE 6:e26973. 2011
    ..was used to compare sublingual administration with intranasal and intramuscular administration of influenza H5N1 virosomes (2 µg haemagglutinin; HA) in combination with the mucosal adjuvant (3',5')-cyclic dimeric guanylic acid (c-di-..
  5. ncbi Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine
    Christian Herzog
    Berna Biotech AG, Rehhagstrasse 79, 3018 Berne, Switzerland
    Vaccine 27:4381-7. 2009
    ..This review presents and discusses the experience with Inflexal V during the past decade...
  6. pmc Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes
    Geert Leroux-Roels
    Center for Vaccinology CEVAC, Ghent University Hospital, Ghent, Belgium
    PLoS ONE 8:e55438. 2013
    ..The study objectives were to assess the safety, tolerability and immunogenicity of virosomes harboring surface HIV-1 gp41-derived P1 lipidated peptides (MYM-V101)...
  7. ncbi Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs
    Diana Felnerova
    Berna Biotech Ltd, Rehhagstrasse 79, CH 3018, Berne, Switzerland
    Curr Opin Biotechnol 15:518-29. 2004
    ....
  8. ncbi Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation
    Toon Stegmann
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen and University of Groningen, 9700 RB, Groningen, The Netherlands
    Vaccine 28:5543-50. 2010
    ..Here we show that immunization of mice with reconstituted virosomes produced from RSV envelopes and containing the lipopeptide adjuvant (P3CSK4), induces high-titer virus-..
  9. ncbi Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs
    J De Jonge
    University Medical Center Groningen, Department of Medical Microbiology, Groningen, The Netherlands
    Gene Ther 13:400-11. 2006
    ..Here, we present reconstituted viral envelopes (virosomes) derived from influenza virus as suitable vehicles for in vitro as well as in vivo delivery of siRNAs...
  10. ncbi Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool
    Yasufumi Kaneda
    Osaka University, Graduate School of Medicine, Division of Gene Therapy Science, Suita, Osaka, Japan
    Expert Opin Drug Deliv 7:1079-93. 2010
    ..Non-viral delivery methods have been utilized to enhance the tumor-selective delivery of therapeutic molecules, including proteins, synthetic oligonucleotides, small compounds and genes...
  11. pmc Pseudovirions as vehicles for the delivery of siRNA
    Paul E Lund
    Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Pharm Res 27:400-20. 2010
    ..discussed in this review, namely phagemids, HSV amplicons, SV40 in vitro-packaged vectors, influenza virosomes, and HVJ-Envelope vectors, make them attractive for the delivery of siRNA-based therapeutics...
  12. ncbi The cellular endosomal sorting complex required for transport pathway is not involved in avian metapneumovirus budding in a virus-like-particle expression system
    Yuejin Weng
    Department of Biology and Microbiology, South Dakota State University, Brookings, SD 57007, USA
    J Gen Virol 92:1205-13. 2011
    ..Taken together, these results suggest that metapneumovirus budding is independent of the ESCRT pathway and the minimal budding machinery described here will aid our future understanding of metapneumovirus assembly and egress...
  13. ncbi Influenza virosomes as a vaccine adjuvant and carrier system
    Christian Moser
    Pevion Biotech AG, CH 3063 Ittigen, Switzerland
    Expert Rev Vaccines 10:437-46. 2011
    Influenza virosomes have been used for more than 10 years in commercial vaccines. The technology has been further developed as a carrier and adjuvant system for subunit vaccines, in particular for synthetic peptides...
  14. ncbi Virosome-mediated delivery of protein antigens to dendritic cells
    Laura Bungener
    Department of Medical Microbiology, Molecular Virology Section, University of Groningen, Groningen, The Netherlands
    Vaccine 20:2287-95. 2002
    b>Virosomes are reconstituted viral membranes in which protein can be encapsulated...
  15. ncbi Virus-like particles: passport to immune recognition
    Elizabeth V L Grgacic
    Macfarlane Burnet Institute for Medical Research and Public Health, 85 Commercial Road, Melbourne 3004, Australia
    Methods 40:60-5. 2006
    ..This review outlines some of the advantages, disadvantages, and technical considerations for the use of a wide range of VLP systems in vaccine development...
  16. ncbi 4th meeting on Novel Adjuvants Currently in/close to Human Clinical Testing World Health Organization -- organisation Mondiale de la Santé Fondation Mérieux, Annecy, France, 23-25, June 2003
    J Richard Pink
    World Health Organization IVR, Geneva, Switzerland
    Vaccine 22:2097-102. 2004
  17. ncbi Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity
    Anke Huckriede
    Department of Medical Microbiology, University of Groningen, A Deusinglaan 1, Groningen AV 9713, The Netherlands
    Vaccine 21:925-31. 2003
  18. ncbi Influenza virosomes as an efficient system for adjuvanted vaccine delivery
    Reinhard Gluck
    Berna Biotech Ltd, Rehhagstrasse 79, Berne, Switzerland
    Expert Opin Biol Ther 4:1139-45. 2004
    Immunopotentiating reconstituted influenza virosomes possess several characteristics defining them as vaccine adjuvants...
  19. ncbi In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus
    Isabelle P Hunziker
    Clinic of Rheumatology and Clinical Immunology Allergology, University Hospital, Inselspital, 3010 Bern, Switzerland
    Int Immunol 14:615-26. 2002
    ..this study is to describe a novel non-live prototype vaccine based on immunopotentiating reconstituted influenza virosomes (IRIV) as vehicles to deliver HLA-A*0201-restricted hepatitis C virus (HCV) peptides (core 35-44 and 131-140) ..
  20. ncbi Targeting her-2/neu with antirat Neu virosomes for cancer therapy
    Ernst Waelti
    Department of Clinical Research, University of Bern, 3010 Bern, Switzerland
    Cancer Res 62:437-44. 2002
    ..We have used virosomes (Vir; reconstituted fusion-active viral envelopes) as a new drug delivery system and have shown that Vir are ..
  21. ncbi Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation
    Reto Schumacher
    Department of Surgery, University of Basel, Basel, Switzerland
    Vaccine 22:714-23. 2004
    Immunopotentiating reconstituted influenza virosomes (IRIV) are one of the few adjuvants currently licensed for human use...
  22. ncbi Modified influenza virosomes: recent advances and potential in gene delivery
    M Khoshnejad
    School of Biomedical Sciences, University of Queensland, Brisbane, QLD 4072, Australia
    Curr Med Chem 14:3152-6. 2007
    Influenza virosomes have proven to be effective vehicles for the delivery of antigens in the vaccination of humans against a number of pathogens. However, their potential as a means for gene delivery has yet to be realized...
  23. ncbi Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination
    Abbas Jamali
    Influenza Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Immunol Lett 148:77-82. 2012
    ..and characterized a new and safe adjuvanted delivery system for DNA vaccination using cationic influenza virosomes (CIV)...
  24. ncbi Cellular delivery of siRNA mediated by fusion-active virosomes
    Anke Huckriede
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    J Liposome Res 17:39-47. 2007
    ..This paper focuses on the use of reconstituted viral envelopes ("virosomes"), derived from influenza virus, as a carrier system for cellular delivery of siRNA...
  25. ncbi Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes
    P Correale
    Medical Oncology Division, Medicine School, Siena University, 53100, Siena, Italy
    Eur J Cancer 37:2097-103. 2001
    We investigated influenza virosomes as a TAA-gene delivery system for use in TAA-directed anti-cancer vaccine therapy...
  26. ncbi Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage
    Jørgen de Jonge
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands
    Eur J Pharm Sci 32:33-44. 2007
    Influenza virosomes are reconstituted influenza virus envelopes that may be used as vaccines or as carrier systems for cellular delivery of therapeutic molecules...
  27. ncbi Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate
    Xinyu Liu
    Laboratorium fur Organische Chemie, ETH Zurich, Wolfgang Pauli Strasse 10, 8093 Zurich, Switzerland
    ACS Chem Biol 1:161-4. 2006
    ..These glycan conjugates were embedded into the lipid membrane of reconstituted influenza virus virosomes. The virosomal formulations elicited both IgM and IgG anti-glycan antibodies in mice, indicating an antibody ..
  28. ncbi Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma
    Gianvincenzo Zuccotti
    Department of Pediatrics, University of Milan, Luigi Sacco Hospital, Via GB Grassi 74, 20157 Milan, Italy
    Vaccine 25:6692-8. 2007
    ..However, while immunity response and persistence are excellently high in children with pre-existing antibodies, in children naive for the antigens the immune parameters are lower at 6 months after vaccination...
  29. pmc Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA
    Jørgen de Jonge
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands
    Biochem J 405:41-9. 2007
    Reconstituted influenza virosomes (virus membrane envelopes) have been used previously to deliver pDNA (plasmid DNA) bound to their external surface to a variety of target cells...
  30. ncbi Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells
    Juliette Angel
    INSERM, U823, Centre de Recherche Albert Bonniot, La Tronche F 38706, France
    Vaccine 25:3913-21. 2007
    ..relies on a novel antigen delivery system termed "chimeric immunopotentiating reconstituted influenza virosomes" (CIRIV) targeting plasmacytoid dendritic cells (PDC)...
  31. ncbi Establishment of a neutralization test involving reporter gene-expressing virus-like particles of tick-borne encephalitis virus
    Kentaro Yoshii
    Laboratory of Public Health, Graduate School of Veterinary Medicine, Hokkaido University, Kita 18 Nishi 9, Kita ku, Sapporo, Hokkaido, Japan
    J Virol Methods 161:173-6. 2009
    ..These results indicate that VLPs that express reporter genes represent a useful and safe alternative to conventional neutralization testing using live virus...
  32. ncbi Virosomes for antigen and DNA delivery
    Toos Daemen
    Department of Medical Microbiology, Molecular Virology Section, University of Groningen, Anthonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Adv Drug Deliv Rev 57:451-63. 2005
    ..Among other delivery systems, as described in this theme issue of Advanced Drug Delivery Reviews, virosomes seem ideally suited for delivery of antigens into both MHC pathways...
  33. ncbi Adjuvant and antigen delivery properties of virosomes
    Reinhard Gluck
    Berna Biotech Ltd, Rehhagstrasse 79, 3018 Berne, Switzerland
    Curr Drug Deliv 2:395-400. 2005
    ..The most significant progress to date has been made with virosomes, a novel antigen delivery system that incorporates the haemagglutinin from influenza virus into liposomes and ..
  34. pmc Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1
    Markus S Mueller
    Molecular Immunology, Swiss Tropical Institute, CH 4002 Basel, Switzerland
    Infect Immun 71:4749-58. 2003
    ..the phosphatidylethanolamine-peptide conjugate was incorporated into immunopotentiating reconstituted influenza virosomes as a human-compatible antigen delivery system...
  35. ncbi Virosomes: evolution of the liposome as a targeted drug delivery system
    Y Kaneda
    Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Suita, 565 0871, Osaka, Japan
    Adv Drug Deliv Rev 43:197-205. 2000
    ..To enhance the efficiency of gene delivery by the introduction of molecules directly into cells, virosomes have been developed by combining liposomes with fusiogenic viral envelope proteins...
  36. pmc A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers
    Blaise Genton
    Swiss Tropical Institute, Basel, Switzerland
    PLoS ONE 2:e1018. 2007
    Influenza virosomes represent an innovative human-compatible antigen delivery system that has already proven its suitability for subunit vaccine design...
  37. ncbi Targeting influenza virosomes to ovarian carcinoma cells
    E Mastrobattista
    Utrecht Institute for Pharmaceutical Sciences, Department of Pharmaceutics, Utrecht University, The Netherlands
    FEBS Lett 509:71-6. 2001
    Reconstituted influenza virus envelopes (virosomes) containing the viral hemagglutinin (HA) have attracted attention as delivery vesicles for cytosolic drug delivery as they possess membrane fusion activity...
  38. ncbi Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation
    Shinji L Okitsu
    Molecular Immunology, Swiss Tropical Institute, CH 4002 Basel, Switzerland
    Chem Biol 14:577-87. 2007
    ..Intramuscular delivery of UK-39 to mice and rabbits on the surface of reconstituted influenza virosomes elicited high titers of sporozoite crossreactive antibodies...
  39. ncbi Virosomes can enter cells by non-phagocytic mechanisms
    Ursula Hofer
    Institute of Anatomy, Division of Histology, University of Bern, Switzerland
    J Liposome Res 19:301-9. 2009
    ..2 microm) in macrophages occurs also by other mechanisms. Virosomes with a diameter of 0.12-0...
  40. ncbi Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial
    Orlando Mayorga Pérez
    Department of Microbiology and Parasitology, Faculty of Medicine, University of Leon, Nicaragua
    J Infect Dis 188:671-7. 2003
    ..6 cases/100 person-years. Adverse effects were rare in both children in the vaccine group and children in the placebo group. A single dose of a hepatitis A virosome vaccine is safe and protects young children against HAV infection...
  41. ncbi Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs
    Laura Bungener
    Department of Medical Microbiology, University of Groningen, The Netherlands
    Biosci Rep 22:323-38. 2002
    ..These systems comprise reconstituted virus envelopes (virosomes), liposomes, and immune-stimulating complexes (ISCOMs)...
  42. ncbi Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations
    Christian Moser
    Pevion Biotech, Rehhagstrasse 79, 3018 Bern, Switzerland
    Expert Rev Vaccines 6:711-21. 2007
    Influenza virosomes are an efficient antigen carrier and adjuvant system that are approved for the use in human vaccines...
  43. ncbi Applications of influenza virosomes as a delivery system
    Maria Grazia Cusi
    Department of Molecular Biology, University of Siena, Siena, Italy
    Hum Vaccin 2:1-7. 2006
    ..In this review, we will discuss influenza virosomes as a versatile delivery system for molecules of a different nature, such as proteins, peptides and nucleic acids...
  44. ncbi Synthesis, solution structure and immune recognition of an epidermal growth factor-like domain from Plasmodium falciparum merozoite surface protein-1
    Sonya James
    Department of Chemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
    Chembiochem 7:1943-50. 2006
    ..through its N terminus to a phospholipid and incorporated into reconstituted influenza virus-like particles (virosomes)...
  45. ncbi Immunostimulating reconstituted influenza virosomes
    Rinaldo Zurbriggen
    Pevion Biotech Ltd, Rehhagstrasse 79, Bern 3018, Switzerland
    Vaccine 21:921-4. 2003
    Immunostimulating reconstituted influenza virosomes (IRIVs) are a liposomal carrier system. Influenza hemagglutinin and neuraminidase are intercalated into the lipid bilayer and give the IRIVs their fusogenic activity...
  46. ncbi Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice
    Abdullah S Madhun
    Influenza Centre, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Vaccine 27:7367-76. 2009
    ..Our results highlight that Matrix-M adjuvant is a promising parenteral adjuvant for formulating pandemic candidate vaccines...
  47. ncbi Efficient delivery of DNA to dendritic cells mediated by influenza virosomes
    Maria Grazia Cusi
    Department of Molecular Biology, Microbiology Section, University of Siena, Via Laterina 8, 53100 Siena, Italy
    Vaccine 22:735-9. 2004
    ..For this purpose we investigated influenza virosomes (IRIV) with assembled DNA as a possible biological carrier for targeting the APC in vivo and in vitro...
  48. ncbi Influenza vaccines: the virosome concept
    Jan Wilschut
    Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Immunol Lett 122:118-21. 2009
    Influenza virosomes are virus-like particles, which retain the cell binding and membrane fusion properties of the native virus, but lack the viral genetic material...
  49. ncbi Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design
    R Moreno
    Swiss Tropical Institute, Socinstrasse 57, 4002 Basel, Switzerland
    Chembiochem 2:838-43. 2001
    ..we investigate the application of cyclic peptidomimetics presented on immunopotentiating reconstituted influenza virosomes (IRIVs), a form of antigen delivery that is licensed already for human clinical use, in synthetic vaccine design...
  50. ncbi Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes
    Nicole Westerfeld
    Pevion Biotech Ltd, Bern, Switzerland
    Wien Klin Wochenschr 118:50-7. 2006
    ..Here, we review the development of a new approach combining peptide-based malaria vaccine candidate antigens with an immune stimulatory carrier-system based on influenza virosomes focusing on the induction of protective antibodies.
  51. ncbi Adjuvants enhancing an integral immune response to antigens. 15-17 September, 2004, Modern Vaccine/Adjuvant Formulation: impact on future development (MVAF 2004), Prague
    Jan Willem van der Laan
    National Institute for Public Health and the Environment, Centre for Biological Medicines and Medical Technology, The Netherlands
    Expert Rev Vaccines 4:15-8. 2005
  52. ncbi Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes
    Kazunari Kondo
    Center for Pathogen Genomics, National Institute of Infectious Diseases, Shinjuku ku, Tokyo, Japan
    J Med Virol 80:841-6. 2008
    ..Although the cross-neutralizing titers were lower than the type-specific neutralizing titer, the results suggest that the chimeric VLPs have potential to serve as a vaccine candidate for a broad spectrum of high-risk HPVs...
  53. pmc An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles
    Luca Santi
    The Biodesign Institute and School of Life Sciences, Arizona State University, Tempe, AZ 85287 5401, USA
    Vaccine 26:1846-54. 2008
    ..We conclude that the plant viral transient expression system provides a robust research tool to generate abundant quantities of rNV as enriched, concentrated VLP preparations that are orally immunogenic...
  54. ncbi The virosome concept for influenza vaccines
    Anke Huckriede
    University Medical Center Groningen, Department of Medical Microbiology, Molecular Virology Section, University of Groningen, Ant Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Vaccine 23:S26-38. 2005
    ..In this context, there is considerable interest in virosomes. Virosomes are virus-like particles, consisting of reconstituted influenza virus envelopes, lacking the genetic ..
  55. ncbi Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles
    Yufei Xu
    Department of Biophysics and Structural Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    FEMS Immunol Med Microbiol 52:99-109. 2008
    ..The results suggested that it is possible to enhance the immunogenicity of HPV VLP vaccines via a strategy of fusing effective adjuvant protein into cVLPs...
  56. ncbi Particulate delivery systems for animal vaccines
    Jean Pierre Y Scheerlinck
    The Centre for Animal Biotechnology, The University of Melbourne, VIC 3010, Australia
    Methods 40:118-24. 2006
    ..Here, we review particulate vaccine delivery systems, ranging from cm-sized long-distance ballistic devices to nano-bead technology for veterinary species and wildlife...
  57. ncbi Virus-like particles: designing an effective AIDS vaccine
    Kelly R Young
    Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, PA 15261, USA
    Methods 40:98-117. 2006
    ..A variety of VLPs for lentiviruses are currently in preclinical and clinical trials. This review focuses on our current status of VLP-based AIDS vaccines, regarding issues of purification and immune design for animal and clinical trials...
  58. ncbi Lipid based particulate formulations for the delivery of antigen
    Melissa J Copland
    Drug Delivery Solutions, School of Pharmacy, University of Otago, Dunedin, New Zealand
    Immunol Cell Biol 83:97-105. 2005
    ..This article discusses lipid based particulate systems, grouped according to the nature of their predominant lipid constituent...
  59. ncbi The effect of pre-existing immunity on the capacity of influenza virosomes to induce cytotoxic T lymphocyte activity
    Arjan de Mare
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Vaccine 26:2314-21. 2008
    Protein antigens encapsulated in virosomes generated from influenza virus can induce antigen-specific cytotoxic T lymphocyte (CTL) responses...
  60. ncbi Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform
    Jérôme Denis
    Centre de Recherche en Infectiologie, Pavillon CHUL, Universite Laval, 2705 Boulevard Laurier, Quebec, PQ, G1V 4G2 Canada
    Vaccine 26:3395-403. 2008
    ..These results show, for the first time, the potential of a recombinant plant virus protein to serve as both peptide delivery system and adjuvant in the crucial field of influenza vaccine development...
  61. ncbi Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system
    Tomoyuki Kakudo
    Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita ku, Sapporo 060 0812, Japan
    Biochemistry 43:5618-28. 2004
    ..With GALA present on the surface, intracellular trafficking of liposomes after receptor-mediated endocytosis could be successfully controlled...
  62. ncbi Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice
    Claudia Istrate
    Instituto de Biologia Experimental e Tecnologica and Instituto de Tecnologia Quimica e Biologica, SE 171 76 Oeiras, Portugal
    Vaccine 26:4594-601. 2008
    ..Passive protective immunity was achieved in offspring to dams vaccinated with 2 and 20 microg RV-VLPs in presence of adjuvant and 20 microg RV-VLP without adjuvant...
  63. pmc longitudinal analysis of levels of immunoglobulins against BK virus capsid proteins in kidney transplant recipients
    P Randhawa
    Department of Pathology, Division of Transplant Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Clin Vaccine Immunol 15:1564-71. 2008
    ..25; P = 0.05). In summary, serial measurements of anti-BKV immunoglobulin class (i) detect onset of viral replication, (ii) document episodes of seroreversion, and (iii) can potentially provide prognostic information...
  64. ncbi [Influenza vaccination: advantages of new generation carriers]
    B Bruzzone
    Istituto di Igiene e Medicina Preventiva, Dipartimento di Scienze della Salute, Universita degli Studi di Genova
    Ann Ig 14:11-8. 2002
  65. ncbi Liposomes and ISCOMs
    Gideon F A Kersten
    Laboratory for Product and Process Development, National Institute of Public Health and the Environment, PO Box 1, 3720 BA, Bilthoven, The Netherlands
    Vaccine 21:915-20. 2003
    ..Clinical trials with ISCOMs are in progress and registered liposomal vaccines exist. Here, follows a brief overview on recent developments with emphasis on pharmaceutical aspects...
  66. ncbi Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity
    M G Cusi
    Department of Molecular Biology, University of Siena, Via Laterina, 8 53100, Siena, Italy
    Vaccine 20:3436-42. 2002
    ..a new potential vaccine constituted of the respiratory syncytial virus (RSV)-F protein associated with influenza virosomes (RSV-F/IRIV) in combination with the mucosal adjuvant Escheriagen (Escherichia coli heat-labile toxin), ..
  67. ncbi Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine
    Rob Lambkin
    Department of Medical Microbiology and Retroscreen Virology, St Bartholomew s and The Royal London, Queen Mary School of Medicine and Dentistry, University of London, 327 Mile End Road, London E1 4NS, UK
    Vaccine 22:4390-6. 2004
    ..Recent investigations of virosomes as delivery systems for viral HA and NA antigens have demonstrated an improved immune response...
  68. ncbi Effects of temperature on viral glycoprotein mobility and a possible role of internal "viroskeleton" proteins in Sendai virus fusion
    S Ohki
    Department of Physiology and Biophysics, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, 3435 Main Street, Buffalo, NY 14214, USA
    J Membr Biol 199:73-83. 2004
    ..On the other hand, reconstituted viral envelopes (virosomes) bearing viral glycoproteins but lacking matrix proteins were capable of fusing with erythrocyte ghosts even at ..
  69. ncbi Lipid composition of virosomes modulates their fusion efficiency with cryopreserved bull sperm cells
    K Markgraf
    BioS Biotechnology Schoenow GmbH, Schoenow, Germany
    Cloning 3:11-21. 2001
    b>Virosomes derived from different fusogenic enveloped viruses have been generated for potential application in gene targeting to sperm cells...
  70. ncbi Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial
    Michel Adamina
    Institute for Surgical Research and Hospital Management, Department of Surgery, University of Basel, Hebelstrasse 20, 4031 Basel, Switzerland
    Contemp Clin Trials 29:165-81. 2008
    ..AJCC stages IIb-IV melanoma patients will be treated, first with melanoma epitopes included into Influenza virosomes (group 1), and second with a heterologous prime-boost protocol priming with a recombinant Vaccinia virus, and ..
  71. ncbi Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses
    Dana L Swenson
    US Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, MD 21702 5011, USA
    Expert Rev Vaccines 7:417-29. 2008
    ..Guinea pigs vaccinated with Marburg virus VLPs (mVLPs) or inactivated MARV (iMARV) develop homologous humoral and T-cell responses and are completely protected from a lethal homologous MARV challenge...
  72. ncbi Prophylactic HPV vaccines: reducing the burden of HPV-related diseases
    Luisa Lina Villa
    Ludwig Institute for Cancer Research, Sao Paulo branch Rua Prof Antonio Prudente, 109, 4o andar, 01509 010 Sao Paulo, SP, Brazil
    Vaccine 24:S23-8. 2006
    ....
  73. pmc Human immunodeficiency virus-like particles activate multiple types of immune cells
    Gangadhara Sailaja
    Emory Vaccine Center and Department of Microbiology and Immunology, Rollins Research Center 3086, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA
    Virology 362:331-41. 2007
    ..VLPs containing FL were an effective form of antigen in activating immune cells via dendritic cells, and immunization with HIV VLPs containing FL resulted in enhanced T helper type 2-like immune responses...
  74. ncbi Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition
    A de Mare
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Gene Ther 15:393-403. 2008
    ..These results suggest that, apart from vector-specific antibodies or killing of infected cells, T-cell competition may be involved in determining the efficacy of viral vector-based prime-boost immunization regimens...
  75. ncbi Gene therapy: optimising DNA delivery to the nucleus
    M Johnson-Saliba
    Nuclear Signalling Laboratory, John Curtin School of Medical Research, Australian National University, Canberra, ACT
    Curr Drug Targets 2:371-99. 2001
    ....
  76. pmc Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design
    Peng H Tan
    Department of Immunology, Division of Medicine, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK
    Mol Med 13:216-26. 2007
    ..Preformed virion-liposome complexes, termed virosomes, have been reported to be relatively stable...
  77. ncbi Expression of DeltaF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR
    K K Goncz
    Human Molecular Genetics, Department of Medicine, University of Vermont, Burlington, VT, USA
    Gene Ther 8:961-5. 2001
    ..The results of these studies showed that SFHR can be used as a gene therapy to introduce specific modifications into the cells of clinically affected organs and that the cells will express the new sequence...
  78. ncbi Gene transfection by quantitatively reconstituted Sendai envelope proteins into liposomes
    Hong Sung Kim
    Department of Medical Technology, Yonsei University, Wonju 220 710, Republic of Korea
    Cancer Gene Ther 9:173-7. 2002
    Fusogenic liposomes (virosomes) consisting of Sendai virus envelope proteins have been utilized for in vitro and in vivo genetic modification of animal cells...
  79. ncbi Characterization of the gene delivery properties of baculoviral-based virosomal vectors
    Ghiabe Henri Guibinga
    Department of Pediatrics, Center for Molecular Genetics, University of California San Diego School of Medicine, La Jolla, CA 92093 0634, USA
    J Virol Methods 148:277-82. 2008
    ..This difference may be explained in part by the dissimilarity in the fusogenic properties of their respective viral glycoprotein...
  80. ncbi Various carrier system(s)- mediated genetic vaccination strategies against malaria
    Rajeev K Tyagi
    Biomedical Parasitology Unit, Pasteur Institute, 25 28 Rue du Dr Roux, 75724 Paris Cedex 15, France
    Expert Rev Vaccines 7:499-520. 2008
    ..This has encouraged the development of nonviral DNA-mediated gene-transfer techniques, such as liposomes, virosomes, microspheres and nanoparticles...
  81. pmc Vaccinia virus particles mix inefficiently, and in a way that would restrict viral recombination, in coinfected cells
    Y C James Lin
    Alberta Institute for Viral Immunology and Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, The University of Alberta, Alberta, Canada
    J Virol 84:2432-43. 2010
    ..Poxviruses replicate in membrane-wrapped cytoplasmic structures called virosomes (or factories) and we have developed a method for tracking the development of these structures using live cell ..
  82. ncbi Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines
    P A Bovier
    Travel and Migration Medicine Unit, Department of Community Medicine, Geneva University Hospital, Geneva, Switzerland
    J Travel Med 6:228-33. 1999
    ..of this study was to evaluate the tolerance and immunogenicity of a hepatitis A vaccine using immunopotentiating reconstituted influenza virosomes (IRIV) as adjuvant when administered simultaneously with a yellow fever vaccine (YFV).
  83. pmc Vaccinia virus DNA ligase recruits cellular topoisomerase II to sites of viral replication and assembly
    Y C James Lin
    Department of Medical Microbiology and Immunology, Alberta Institute for Viral Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada
    J Virol 82:5922-32. 2008
    ..Immunoelectron microscopy confirmed the presence of topoisomerases IIalpha/beta in virosomes, but the enzyme could not be detected in mature virus particles...
  84. ncbi Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV)
    R Gluck
    Swiss Serum and Vaccine Institute, Berne
    Dev Biol (Basel) 103:189-97. 2000
    ..a potent and well tolerated adjuvant has focussed on the use of immunopotentiating reconstituted influenza virosomes (IRIV)...
  85. pmc Elucidating the essential role of the A14 phosphoprotein in vaccinia virus morphogenesis: construction and characterization of a tetracycline-inducible recombinant
    P Traktman
    Department of Microbiology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    J Virol 74:3682-95. 2000
    ..of large numbers of vesicles and the appearance of "empty" crescents that appear to adhere only loosely to virosomes. This phenotype corresponds closely to that observed for an IPTG-inducible A14 recombinant whose construction ..
  86. ncbi Preservation of influenza virosome structure and function during freeze-drying and storage
    Jan Wilschut
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    J Liposome Res 17:173-82. 2007
    b>Virosomes derived from influenza virus are reconstituted viral envelopes, which retain the receptor-binding and cell entry properties of the native virus, but lack the viral genetic material...
  87. ncbi Improvements in gene therapy technologies
    Y Kaneda
    Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
    Mol Urol 5:85-9. 2001
    ..By coupling the Epstein-Barr (EB) virus replicon apparatus with HVJ-liposomes (virosomes), transgene expression was sustained in vitro and in vivo...
  88. pmc Role of hemagglutinin surface density in the initial stages of influenza virus fusion: lack of evidence for cooperativity
    S Gunther-Ausborn
    Department of Biophysical Chemistry, Biozentrum of the University of Basel, CH 4056 Basel, Switzerland
    J Virol 74:2714-20. 2000
    ..to trigger fusion, and to assess the importance of cooperativity between these HA trimers, we have generated virosomes containing coreconstituted HAs derived from two strains of virus with different pH dependencies for fusion, X-47 ..
  89. ncbi Advanced liposomal vectors as cancer vaccines in melanoma immunotherapy
    Michel Adamina
    Institute for Surgical Research and Hospital Management, University of Basel, Basel, Switzerland
    J Liposome Res 16:195-204. 2006
    ..Liposomes and their further development as virosomes with added adjuvancy may address both these issues...
  90. pmc Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine
    Marco Tamborrini
    Swiss Tropical Institute, Molecular Immunology, CH 4002 Basel, Switzerland
    Malar J 8:314. 2009
    ..This report describes the immunological characterization of linear and cyclized synthetic peptides comprising amino acids 211-237 of Plasmodium falciparum merozoite surface protein (MSP-3)...
  91. ncbi An efficient liposomal gene delivery vehicle using Sendai F/HN proteins and protamine
    H S Kim
    Department of Biomedical Laboratory Science, Yonsei University, Wonju, Gangwon, Republic of Korea
    Cancer Gene Ther 15:214-24. 2008
    By means of a simple mixing procedure, we have constructed cationic Sendai virosomes consisting of fusogenic viral F/HN proteins and cationic lipids...
  92. ncbi Immunogenicity and protective efficacy of virosome based vaccines against Newcastle disease
    Rajinder Singh
    Division of Biological Products, Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, India
    Trop Anim Health Prod 42:465-71. 2010
    ..Envelop of Newcastle disease virus (NDV) was solubilised with Triton X-100 to yield virosomes which were later on encapsulated in poly-lactide-co-glycolide (PLG) microspheres...
  93. ncbi Reconstituted coronavirus TGEV virosomes lose the virus ability to induce porcine interferon-alpha production
    S Riffault
    Virologie et Immunologie Moléculaires, INRA, Jouy en Josas, France
    Vet Res 28:105-14. 1997
    ..an attempt to isolate functional envelope proteins, TGEV virions were detergent-solubilized and reconstituted in virosomes. Although BIAcore antigenic analysis revealed that the three external viral proteins were present on the ..
  94. ncbi Reconstituted coronavirus TGEV virosomes lose the virus ability to induce porcine interferon-alpha production
    S Riffault
    Virologie et Immunologie Moléculaires, INRA, Jouy en Josas, France
    Vet Res 28:77-86. 1997
    ..an attempt to isolate functional envelope proteins, TGEV virions were detergent-solubilized and reconstituted in virosomes. Although BIAcore antigenic analysis revealed that the three external viral proteins were present on the ..
  95. ncbi Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity
    M G Cusi
    Department of Molecular Biology, Section of Microbiology, University of Siena, Via Laterina 8, Siena, 53100, Italy
    Virology 277:111-8. 2000
    ..The administration of this DNA vaccine delivered by influenza virosomes, in combination with the mucosal adjuvant Escheriagen via the intranasal route, was efficient for inducing an ..
  96. ncbi [Development of vaccine adjuvants using polymeric nanoparticles and their potential applications for anti-HIV vaccine]
    Takami Akagi
    Department of Applied Chemistry, Graduate School of Engineering, Osaka University, Yamadaoka, Suita City, Japan
    Yakugaku Zasshi 127:307-17. 2007
    ..Particulate adjuvants (e.g. micro/nanoparticles, emulsions, ISCOMS, liposomes, virosomes, and virus-like particles) have been widely investigated as HIV-1 vaccine delivery systems...
  97. ncbi Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization
    R Glueck
    Swiss Serum and Vaccine Institute, 3018, Bern, Switzerland
    Vaccine 20:S42-4. 2001
    ..It consists of influenza virosomes which are formulated from inactivated influenza strains and heat-labile toxin from aseptic Escherichia coli ..
  98. ncbi Immunopotentiating reconstituted influenza virosomes as a novel antigen delivery system
    S J Cryz
    Swiss Serum and Vaccine Institute, Bern, Switzerland
    Dev Biol Stand 92:219-23. 1998
    Using immunopotentiating, reconstituted influenza virosomes (IRIV) as a delivery vehicle, a number of vaccines have been developed...
  99. ncbi Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity
    J J C De Vries
    Department of Medical Microbiology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands
    Vaccine 27:947-55. 2009
    ..Inactivated influenza H5N1 virus (NIBRG-14) was used to construct virosomes (reconstituted virus envelopes) with LpxL1 incorporated in the virosomal membrane thus combining the influenza ..
  100. ncbi Adjuvants and autoimmunity
    E Israeli
    Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel
    Lupus 18:1217-25. 2009
    ..including MF59 in some viral vaccines, MPL, AS04, AS01B and AS02A against viral and parasitic infections, virosomes for HBV, HPV and HAV, and cholera toxin for cholera...
  101. ncbi Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes)
    E R Waelti
    Institute of Pathology, University of Bern, Switzerland
    Int J Cancer 77:728-33. 1998
    ..phosphorothioates (OPTs) of L-myc were encapsulated into reconstituted influenza-virus-A envelopes (virosomes). The envelopes of the virosomes consisted of a single positively charged (cationic) lipid bilayer...

Research Grants12

  1. Adjuvants and Virosomal Vaccines for the Elderly
    Janet E McElhaney; Fiscal Year: 2011
    ..age-related declines in the cell-mediated immune response to influenza vaccination may be enhanced by adjuvants/virosomes in older adults...
  2. KINETICS AND MECHANISMS OF VIRUS-CELL MEMBRANE FUSION
    Nejat Duzgunes; Fiscal Year: 1992
    ..We will reconstitute these proteins in phospholipid vesicles, to produce "virosomes" which have the same requirements for fusion (such as pH) as the intact virus...
  3. DEVELOPMENT OF CFTR AS A THERAPEUTIC PROTEIN
    Alan Smith; Fiscal Year: 1991
    ..Plasma membrane preparations, blebs, virosomes, and liposomes all containing viral glycoproteins and CFTR will be used to target to CF airway cells and ion ..
  4. MEMBRANE FUSION
    JOSEPH BENTZ; Fiscal Year: 1992
    ..on the role of cell surface receptors on the fusion mechanism using intact virus and reconstituted systems, virosomes, which we will develop into a reliable method for delivery of macromolecules into cells...
  5. PARAMYXOVIRUS MEMBRANE FUSION
    TRUDY MORRISON; Fiscal Year: 2005
    ..4) explore the role of attachment in initiation of fusion. ..
  6. Cloning Kawasaki Disease-specific antigens
    Anne Rowley; Fiscal Year: 2005
    ..These plans will provide me with opportunities for enhanced career development by acquisition of new research skills, and will be fostered by the strong interdisciplinary research environment at Northwestern. ..
  7. Inhibiting poxvirus phosphatases: therapy and biodefense
    Paula Traktman; Fiscal Year: 2004
    ..Compounds that significantly affect viral infectivity in cellular assays will have high potential for study in animal models and for further development to human therapeutics. ..
  8. VACCINIA ENCODED KINASES AND PHOSPHATASES
    Paula Traktman; Fiscal Year: 2003
    ....
  9. JEOL 2100 LaB6 Transmission Electron Microscope with GATAN Ultrascan 1000 Camera
    Paula Traktman; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  10. VACCINIA ENCODED KINASES AND PHOSPHATASES
    Paula Traktman; Fiscal Year: 2009
    ....
  11. Immune Response to Polyomavirus Infection
    Parmjeet S Randhawa; Fiscal Year: 2010
    ..This, in turn, will help us to better predict the clinical course of the disease in individual patients, and help devise more effective forms of anti-viral therapy. ..